Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
J Cutan Pathol ; 47(4): 328-338, 2020 Apr.
Article in English | MEDLINE | ID: mdl-31837051

ABSTRACT

BACKGROUND: While patients are the ultimate beneficiaries of pathology services, pathologist to clinician communication is an essential component of excellent patient care. OBJECTIVE: To survey dermatologists on how well pathologists communicate with them and to assess which aspects of pathologists' communication skills are deemed most significant to dermatologists, stratified by practice type. METHODS: A survey-based instrument was developed and sent to dermatologists through various email listservs. Of the approximately 400 potential Association of Professors of Dermatology respondents, 64 returned the survey questionnaire (response rate 16%). Of the 79 state and regional dermatologic societies, seven agreed to distribute the survey on their listservs (response rate 9%). RESULTS: Surveyed dermatologists believe that the pathologists with whom they work are meeting expectations in the areas of diagnostic accuracy, communicating pertinent information in a timely fashion, integrating written pathology reports into the electronic medical record, and making a clinically meaningful histopathologic interpretation. Discussion of cost of ancillary testing is an area of improvement. University affiliated dermatologists are more likely to use electronic medical records as their predominant mode of communication compared to community dermatologists with and without academic affiliations. Community dermatologists are more likely to use faxed written pathology reports as their predominant mode of communication. CONCLUSION: Physician-to-physician communication is a key component of effective patient care. When it comes to dermatopathology services, dermatologists appear overall satisfied with the indicators examined, however, potential opportunities for improvement exist.


Subject(s)
Communication , Dermatologists , Pathologists , Surveys and Questionnaires , Female , Humans , Male
2.
4.
J Am Acad Dermatol ; 73(2): 228-36.e2, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26048061

ABSTRACT

BACKGROUND: T-cell receptor (TCR) clonality assessment is a principal diagnostic test in the management of mycosis fungoides (MF). However, current polymerase chain reaction-based methods may produce ambiguous results, often because of low abundance of clonal T lymphocytes, resulting in weak clonal peaks that cannot be size-resolved by contemporary capillary electrophoresis (CE). OBJECTIVE: We sought to determine if next-generation sequencing (NGS)-based detection has increased sensitivity for T-cell clonality over CE-based detection in MF. METHODS: Clonality was determined by an NGS-based method in which the TCR-γ variable region was polymerase chain reaction amplified and the products sequenced to establish the identity of rearranged variable and joining regions. RESULTS: Of the 35 MF cases tested, 29 (85%) showed a clonal T-cell rearrangement by NGS, compared with 15 (44%) by standard CE detection. Three patients with MF had follow-up testing that showed identical, clonal TCR sequences in subsequent skin biopsy specimens. LIMITATIONS: Clonal T-cell populations have been described in benign conditions; evidence of clonality alone, by any method, is not sufficient for diagnosis. CONCLUSION: TCR clonality assessment by NGS has superior sensitivity compared with CE-based detection. Further, NGS enables tracking of specific clones across multiple time points for more accurate identification of recurrent MF.


Subject(s)
Genetic Predisposition to Disease , Mycosis Fungoides/diagnosis , Mycosis Fungoides/genetics , Receptors, Antigen, T-Cell/genetics , Skin Neoplasms/diagnosis , Skin Neoplasms/genetics , Adult , Aged , Cloning, Molecular/methods , DNA, Neoplasm/genetics , Databases, Factual , Electrophoresis/methods , Female , Humans , Male , Middle Aged , Molecular Sequence Data , Neoplasm Recurrence, Local/genetics , Neoplasm Recurrence, Local/pathology , Polymerase Chain Reaction/methods , Prognosis , Retrospective Studies
5.
J Cutan Pathol ; 41(7): 568-75, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24641301

ABSTRACT

BACKGROUND: Activating mutations in BRAF have been observed in up to 60% of melanomas, indicating a pivotal role for kinase deregulation in tumor progression. Vemurafenib is a specific inhibitor of BRAF for treatment of melanomas with activating BRAF V600E mutations and has been a major advancement in melanoma treatment. Treatment with vemurafenib, and to a lesser extent, sorafenib, a relatively non-specific inhibitor of BRAF, has been associated with cutaneous squamous cell carcinoma (SCC). METHODS: Clinical and microscopic characteristics of cutaneous neoplasms were evaluated following vemurafenib administration. RESULTS: Twenty-four of 47 (51%) patients receiving vemurafenib at our institution developed 146 total cutaneous neoplasms, with 75% developing multiple lesions. The median number of lesions in affected patients was three. Body distribution included head/neck (29%), chest/back (21%), upper (23%) and lower extremities (27%). Lesions were biopsied and pathologically showed multiple types of epidermal tumors including, but not limited to, verrucous keratoses with/without partial thickness dysplasia, actinic keratoses and well-differentiated and invasive SCCs with/without keratoacanthomatous features. CONCLUSIONS: We describe the histopathologic findings of skin lesions potentially associated with vemurafenib. Additional investigation is necessary to further elucidate cutaneous neoplasms associated with vemurafenib; however, frequent dermatologic evaluation is warranted in all patients receiving BRAF inhibitors.


Subject(s)
Indoles/adverse effects , Keratoacanthoma/chemically induced , Keratoacanthoma/pathology , Melanoma/drug therapy , Neoplasms, Second Primary/pathology , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Skin Neoplasms/chemically induced , Skin Neoplasms/pathology , Sulfonamides/adverse effects , Adult , Aged , Aged, 80 and over , Humans , Indoles/administration & dosage , Keratoacanthoma/enzymology , Keratoacanthoma/genetics , Male , Melanoma/enzymology , Melanoma/genetics , Middle Aged , Mutation , Neoplasms, Second Primary/enzymology , Neoplasms, Second Primary/genetics , Proto-Oncogene Proteins B-raf/genetics , Skin Neoplasms/enzymology , Skin Neoplasms/genetics , Sulfonamides/administration & dosage , Vemurafenib
6.
Int J Artif Organs ; 36(7): 518-21, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23661554

ABSTRACT

INTRODUCTION: Misplacement of extracorporeal membrane oxygenation (ECMO) venous cannula in the azygos vein has previously been described only in newborns. CASE: For the first time, we report an aberrant ECMO cannula placement in the azygos vein in a child outside neonatal period. History of chronic lung disease and ligation of persistent ductus arteriosus leading to elevated right ventricular pressure was the potential risk factor. CONCLUSIONS: This rare complication should be considered whenever the patient has inadequate venous return on ECMO and it can be easily ruled out with a lateral chest radiograph.


Subject(s)
Azygos Vein , Extracorporeal Membrane Oxygenation/adverse effects , Medical Errors , Vascular Access Devices/adverse effects , Autopsy , Azygos Vein/diagnostic imaging , Azygos Vein/physiopathology , Equipment Design , Extracorporeal Membrane Oxygenation/instrumentation , Fatal Outcome , Female , Hemodynamics , Humans , Infant , Phlebography/methods
7.
Curr Eye Res ; 35(9): 819-27, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20795864

ABSTRACT

PURPOSE: The study of aqueous humor dynamics (AHD) in mice is becoming more prevalent as more strains with elevated intraocular pressure (IOP) are developed. High IOP is usually associated with reduced outflow facility making this one of the more important AHD parameters to evaluate. Ocular measurements in mice require anesthesia that has profound effects on IOP but unknown effects on outflow facility. This study evaluates the effects of anesthesia duration and latanoprost treatment on outflow facility and IOP in BALB/c mice. METHODS: IOPs were measured in conscious and anesthetized mice by tonometry. Outflow facility was evaluated in 15-min intervals at three pressure levels over two 45-min periods. Comparisons were made between latanoprost-treated eyes and untreated contralateral eyes. To determine the effect of anesthesia duration on IOP, a microneedle method was used to follow IOP for 120 min in separate mice. RESULTS: IOP was 9.7 +/- 0.3 mmHg (mean +/- SEM) in conscious mice and 7.1 +/- 0.02 within 10 min of anesthesia initiation (p < 0.01). IOP changed significantly between but not within assessment periods. IOP at 75 min was significantly (p = 0.004) reduced compared to IOP at 15 min after initial anesthesia. In control eyes, outflow facility did not change between the two 45-min assessment periods during the 120 min test (p = 0.80). In latanoprost-treated eyes, outflow facility increased compared with control eyes during both assessment periods (p = 0.03). A test of filters in series with known resistance found that the method was sensitive enough to detect a change in outflow facility of 0.001 microl/min/mmHg. CONCLUSIONS: Administration of ketamine/xylazine anesthesia for 120 min did not alter outflow facility or lessen the effect of latanoprost on outflow facility in mice as determined by a new analysis system. Accurate IOP measurements must be made within minutes of anesthesia administration but outflow facility measurements can be made with less haste.


Subject(s)
Analgesics/administration & dosage , Anesthesia , Anesthetics, Dissociative/administration & dosage , Aqueous Humor/metabolism , Intraocular Pressure/drug effects , Trabecular Meshwork/drug effects , Animals , Antihypertensive Agents/pharmacology , Injections, Intraperitoneal , Ketamine/administration & dosage , Latanoprost , Mice , Mice, Inbred BALB C , Prostaglandins F, Synthetic/pharmacology , Time Factors , Tonometry, Ocular , Trabecular Meshwork/metabolism , Xylazine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...